A Study of Adalimumab to Treat Sarcoidosis of the Skin

Part of paid clinical trials in Norfolk, Virginia.

Sponsor
Pariser, Robert J., M.D.
Study ID
NCT00274352
Phase
PHASE2
Status
Completed

Conditions

  • Sarcoidosis

Eligibility Criteria

Sex
ALL
Age
18 Years - 89 Years
Healthy Volunteers
Not accepted

Interventions

  • adalimumab — DRUG
    Adalimumab 40 mg administered subcutaneously once weekly or placebo injection administered once weekly for 12 weeks, followed by open-label adalimumab 40 mg administered subcutaneously weekly for an additional 12 weeks.

Study Details

The purpose of this study is to determine if adalimumab is an effective for the skin manifestations of sarcoidosis.

Key Dates

Start date
Sep 30, 2006
Status verified
May 2013
Primary completion
Feb 29, 2012
Completion
Feb 29, 2012

Study Design

Enrollment
16 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Primary Outcome Measure

The proportion of subjects who are Responders, achieving at least Moderate Improvement on the Physician's Global Assessment, after 12 weeks of treatment during Period A (double-blind phase). [ Time Frame: at completion of double-blind phase (12 weeks) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Virginia Clinical Research, Inc.NorfolkVirginia23507-

Find similar trials in Norfolk, VA

By research site
Virginia Clinical Research, Inc.· Norfolk, VA

Related Studies